LowCross-Buffer^® 免疫反應干擾降低試劑

Fig. 1 | Western Blotting: Elimination of nonspecific binding. Detection of cytokeratin 4, 5 and 6 is affected by a combination of nonspecific binding and crossreactivities in a dramatic way. The exspected bands can be clearly detected with LowCross-Buffer^®. Lanes 1 and 1' show detection from liver cells; Lanes 2 and 2' show detection from HeLa-cells. Data from Dr. D. Sperling, MACHEREY-NAGEL, Düren

Fig. 2 | ELISA: Elimination of false positive binding. Control of specifity in (A1 – 12) and blanks (H1 – H12) show false positive binding. Data from Dr. C. Specht, vivo Science GmbH, Gronau

Fig. 3 | ELISA: Better sensitivity. With LowCross-Buffer^®, LOD lowered from 0.051 to 0.022 and LOQ from 0.152 to 0.065, in addition to an improved working range. Elimination of cross-reactivities in preimmunsera and reduction of background. Antigen coated, serial dilutions of four immunsera (1:50 to 1:36450) A-G, corresponding preimmunsera in H blank value: column 5. Data from Dr. Ch. Specht, PARA BioScience GmbH, Gronau

Fig. 4 | ELISA: Reduction of background. Reporter antibody is coupled to alkaline phosphatase. It binds nonspecifically and directly to the capture antibody in absence of the analyte. LowCross-Buffer^® prevents this nonspecific binding. Background of the assay is significantly reduced. Shown are blank values without analyte. Data from M. Braun, PD Dr. H.-P. Wendel, Clinic of Thorax-, Cardiac- and Vascular Surgery, research laboratory, University Hospital of Tübingen

Fig. 5 | ELISA: Decrease of the CV. Interference from used human plasma caused a high coefficient of variation (CV) with PBS/BSA Tween (n = 96, determined over the whole measurement range). CV is decreased significantly by using LowCross-Buffer^®. The reason is the avoidance of an interference effect. Thus criteria of the „Guidance for Industry – Bioanalytical Method Validation“ of the FDA could be met. They require for accuracy and precision a maximum of 15%. Data from Dr. P. Rauch, CANDOR Bioscience GmbH

Fig. 6 | ELISA: Elimination of a matrix effect. Matrix effect in an assay for detection of CRP (creactive protein) in rabbit blood plasma. Matrix proteins in plasma mask the analyte CRP. LowCross-Buffer^® demasks the analyte and improves sensitivity and detection limit by a factor of 3. Data from A. Zellmer, Dr. P. Rauch, CANDOR Bioscience GmbH

Fig. 7 | HAMA-ELISA: Active against HAMA and Rheumatoid Factor. The effectiveness of LowCross-Buffer^® towards HAMA and RF derived interferences has been quantified in a CE-certified ELISA (HAMA-ELISA, Medac, Germany) using commercial HAMA and RF positive human blood samples (in. vent diagnostica, Germany). Figure left: HAMA Serum. Figure right: RF Serum.

Fig. 8 | Protein Array: Reduction of background. Multiple antibodies against an identical analyte spotted on a slide. Signal to noise ratio without LowCross-Buffer^® is 3.42, and signal to noise ratio with LowCross-Buffer^® is 17.26. Data from Dipl. Chem. N. Dankbar, University of Münster